Security key
28176E108
Edwards Lifesciences Corp - Common Stock (EW)
CUSIP: 28176E108
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 409,741
- Total 13F value
- $35,323,300
- Share change
- -4,255
- SEC-reported price per share
- $86.32
- Number of holders
- 54
- Value change
- -$434,300
- Number of buys
- 18
- Number of sells
- 19
- Shares outstanding
- 576,625,106
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
54
Top holders
10
EW full security history
Ownership snapshot
Full 13F holder table
Edwards Lifesciences Corp SEC filings
Edwards Lifesciences Corp company facts
Broader feeds
Ownership snapshot
Top reported holders of EW - Edwards Lifesciences Corp - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD CAPITAL MANAGEME...
Disclosed value leader
BlackRock, Inc.
Comparable rows
15/15
Latest evidence
11 Sep 2026
13D/G
13F
3/4/5
Lead comparable stake: 7.5%
13D/G row: VANGUARD CAPITAL MANAGEMENT LLC
Showing 1-6 of 15 holder rows.
Quick read
VANGUARD CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 7.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
VANGUARD CAPITAL MANAGEMENT LLC
7.5%
BlackRock, Inc.
7.5%
WELLINGTON MANAGEMENT GROUP LLP
3.4%
Scott B. Ullem
0.05%
Nicholas J. Valeriani
0.01%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
7.5%
|
$3,481,680,843
43,477,533 shares
|
$0 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.5%
from 13D/G
|
$5,318,092,039
58,789,433 shares
|
— | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
3.4%
|
$1,547,456,998
19,826,483 shares
|
$0 | 30 Jun 2025 |
| Scott B. Ullem |
3/4/5
CVP, Chief Financial Officer
|
0.05%
|
$25,069,684
313,058 shares
|
-$3,874,946 | 11 May 2026 |
| Nicholas J. Valeriani |
3/4/5
Director
|
0.01%
|
$6,760,593
84,423 shares
|
— | 08 May 2026 |
| Steven R. Loranger |
3/4/5
Director
|
0.01%
|
$6,756,268
84,369 shares
|
— | 08 May 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
54
Shares
409,741
Rows available
54
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
1,335
Q3 2026 holders
54
Holder diff
-1,281
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|